Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DRV/r monotherapy versus DRV/r-based triple therapy in virologically suppressed adults with HIV
2008-002383-34Phase 2Completed
- Sponsor
- Janssen Pharmaceutical
- Start
- Oct 2008
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of darunavir and ritonavir in Human immunodeficiency virus infection type 1 (2 arms), sponsored by Janssen Pharmaceutical. Primary endpoint: Change in brachial artery flow-mediated vasodilation from baseline to week 24. Started Oct 2008; status: completed.
02
Drugs
darunavirritonavir
03
Conditions
Human immunodeficiency virus infection type 1
Beyond the preview
Go deeper on 2008-002383-34.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2008-002383-34.